Showing 5141-5150 of 6036 results for "".
- Centricity Vision Appoints Jim Mazzo to its Board of Directorshttps://modernod.com/news/centricity-vision-appoints-jim-mazzo-to-its-board-of-directors/2478353/Centricity Vision announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mr. Mazzo has over 40 years of experience in the ophthalmology industry. His global reputation for building and running world-class organizations is based on 22 years leading Allergan’s North
- Biotech Healthcare Launches Optiflex TRIO Trifocal IOL in Europehttps://modernod.com/news/biotech-healthcare-launches-optiflex-trio-trifocal-iol/2478350/Switzerland-based Biotech Healthcare has announced the European launch of the Optiflex Trio, a diffractive-refractive trifocal toric IOL designed to treat presbyopia and with astigmatism. Its unique diffraction pattern gives a balanced light distribution at all three distances: near, intermediate
- ProQR Announces Virtual Presentations at Euretina and AAOpthttps://modernod.com/news/proqr-announces-virtual-presentations-at-euretina-and-aaopt/2478348/ProQR Therapeutics announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt). ProQR’s presentation at Ophthalmology Futures Retina Forum</
- Inovio’s COVID-19 Vaccine Candidate INO-4800 Hit by FDA Partial Holdhttps://modernod.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/Inovio Pharmaceuticals said that the FDA placed a partial clinical hold on a planned phase 2/3 study of its COVID-19 vaccine candidate INO-4800. According to Inovio, the FDA has “additional questions” about the planned trial, including the CELLECTRA 2000 delivery device to be
- Johnson & Johnson Vision Launches New Eye Care Solutions and Showcases Latest Clinical Data at ESCRS 2020 Virtual Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-launches-new-eye-care-solutions-and-showcases-latest-clinical-data-at-escrs-2020-virtual-annual-meeting/2478335/Johnson & Johnson Vision will launch Tecnis Synergy Toric II IOL with the Tecnis Simplicity Delivery System, a continuous-range-of-vision IOL, at the upcoming virtual European Society of Cataract and Refractive Surgeons (ESCRS) 2020 Annual Meeting, October 2-4. In addition, the company
- Micro Labs USA Launches Two New Glaucoma Drugshttps://modernod.com/news/new-products-launched-by-micro-labs-usa-inc/2478327/Micro Labs USA is launching two products for the treatment of glaucoma in the United States: Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL. Micro Labs USA said there are additional ophthalmic products under developm
- Trump Signs Executive Orders on Preexisting Condition Protections, Surprise Billinghttps://modernod.com/news/trump-signs-executive-orders-on-preexisting-condition-protections-surprise-billing/2478328/President Donald Trump signed an executive order that declares it a national policy to protect patients with preexisting conditions regardless of the fate of the Affordable Care Act (ACA)—but just how they’ll force insurers to comply remains unclear, according to a FierceHealthcare
- House Government Funding Bill Gives Providers Relief on Medicare Advance Paymentshttps://modernod.com/news/house-government-funding-bill-gives-providers-relief-on-medicare-advance-payments/2478324/The House passed a short-term government funding bill that extends the deadline for providers to start repaying Medicare advance payment loans to the end of the COVID-19 public health emergency, according to a FierceHealthcare
- How is Night Vision Maintained During Retinal Disease? Research Provides New Insighthttps://modernod.com/news/how-is-night-vision-maintained-during-retinal-disease-research-provides-new-insight/2478325/New research from a team including scientists from the John A. Moran Eye Center at the University of Utah provides insight on how people with retinal degenerative disease can maintain their night vision for a relatively long period of time. A
- Optimo Medical Gets Support by Innosuisse to Enter the US Markethttps://modernod.com/news/optimo-medical-gets-support-by-innosuisse-to-enter-the-us-market/2478322/Optimo Medical announced that Optimeyes is ready to enter the US market after the FDA decided not to enforce any regulatory requirements, known as enforcement discretion. This important step forward opened the doors for Optimo Medical to receive the additional boost of a Swissnex bootcamp